PERSIAN trial (NCT05717660): an ongoing randomized trial testing androgen deprivation therapy, apalutamide and stereotactic body radiotherapy. An alternative "triplet" for oligometastatic hormone sensitive prostate cancer patients.

Autor: Francolini G; Radiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy. francolinigiulio@gmail.com., Porreca A; Department of Oncological Urology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy., Facchini G; Medical Oncology Unit, SM Delle Grazie Hospital, Naples, Italy., Santini D; Oncologia Medica A, Policlinico Umberto 1, La Sapienza Università Di Roma, Rome, Italy., Bruni A; Radiation Oncology Unit, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy., Simoni N; Radiotherapy Unit, Azienda Ospedaliera Universitaria, Parma, Italy., Trovò M; Department of Radiation Oncology, University General Hospital, Udine, Italy., Osti MF; Department of Radiation Oncology, Sant' Andrea Hospital, Sapienza University of Rome, Rome, Italy., Fornarini G; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Sisani M; Medical Oncology, Usl Toscana Sud est, Arezzo, Italy., Di Cataldo V; Radiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy., Detti B; Radiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy., Garlatti P; Radiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy., Bertini N; Department of Biomedical, Experimental and Clinical Sciences 'Mario Serio', University of Florence, Florence, Italy., Serni S; Unit of Urological Robotic Surgery and Renal Transplantation, Careggi Hospital, University of Florence, Florence, Italy., Minervini A; Unit of Urological Oncologic Minimally Invasive Robotic Surgery and Andrology, Careggi Hospital, University of Florence, Florence, Italy., Livi L; Department of Biomedical, Experimental and Clinical Sciences 'Mario Serio', University of Florence, Florence, Italy.
Jazyk: angličtina
Zdroj: Medical oncology (Northwood, London, England) [Med Oncol] 2023 Dec 29; Vol. 41 (1), pp. 39. Date of Electronic Publication: 2023 Dec 29.
DOI: 10.1007/s12032-023-02268-3
Abstrakt: Earlier treatment intensification with systemic potent androgen receptor inhibition has been shown to improve clinical outcomes in metastatic hormone sensitive prostate cancer. Nonetheless, oligometastatic patients may benefit from local treatment approaches such as stereotactic body radiotherapy (SBRT). Aiming to explore the benefit of SBRT in this scenario, we designed this trial to specifically test the hypothesis that SBRT will improve clinical outcomes in select population affected by metachronous oligometastatic HSPC treated with androgen deprivation therapy + apalutamide. Enrolled patients will be randomized to receive the standard systemic treatment alone or in combination with SBRT on all metastatic sites of disease. Here we report the protocol design and an overview of the ongoing trials testing different integration strategies between RT and systemic therapies.
(© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: